Oncocyte Corporation (OCX) by event type
OCX moves most on rating reiterations — a median of +0.14% at 30 minutes across 26 measured events. Each row is measured over the last three years and read against the price at its own news timestamp. Back to the OCX overview →
How OCX reacts across 2 measured event types.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations 1,104 of 2,283 | 76 | 0.00% | 41% | -0.67% |
| Rating reiterations 633 of 3,522 | 26 | +0.14% | 50% | -0.49% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The rank under each event type orders every name measured for it by median 30-min reaction, most positive first — so a low rank on a downgrade means this name falls harder than most, not that it moves less. Names with an identical median share a rank; a name the cross-section does not carry shows no rank rather than a guessed one. 2 further classes were observed with fewer than 10 measured events and are not published.
That’s how OCX usually reacts — get an email when it moves on news →Every name measured for these event types: Coverage initiations → · Rating reiterations → · OCX overview →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| G1 Therapeutics, Inc. (GTHX) | 142 | +0.21% | 66% |
| InflaRx N.V. (IFRX) | 142 | 0.00% | 48% |
| ImmunoGen, Inc. (IMGN) | 140 | +0.07% | 56% |
| MEDIFIRST SOLUTIONS (MFST) | 140 | 0.00% | 47% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.